The Castle Rock Signal

First Look

Welcome to the Castle Rock VIP Portal

You believed in Castle Rock Hormone Health before the rest of the world caught up, and this portal is built for you. Instead of waiting on a monthly newsletter, you now have a dedicated space where everything you need to know about the industry, our growth, and our momentum is updated weekly and waiting whenever you're ready.

You'll find Signal Reports covering the hottest developments in hormone health, peptides, testosterone, GLP-1s, and menopause, alongside real-time updates from the C-suite, franchise training progress, sales pipeline, and forecasting. No inbox clutter. No delays. Just the freshest intelligence, on your schedule.

"We're not riding a trend. We're building the category standard."

Signal Report · May 2026

Momentum Is Building

$140.86B Peptide Therapeutics Market by 2033

8.73% Projected CAGR 2026–2033

3 Active Growth Initiatives Underway

Science is moving. Demand is rising. Castle Rock is built for what comes next. The peptide therapeutics market is on track to reach $140.86B by 2033, while the FDA moves toward clearer oversight of compounding access, a development that rewards compliant, clinically rigorous operators. TRT demand continues to accelerate, with the TRAVERSE trial removing the last major clinical barrier to mainstream adoption.

Meanwhile, Castle Rock's own roadmap is firing on all cylinders: the Franchise Sidekick platform launches to streamline operations and accelerate unit growth, Castle Rock University raises the bar on provider training and leadership development, and franchise momentum is building toward more locations with a stronger foundation than ever.

Category Signal: The next phase of wellness rewards brands that combine demand with discipline. That's exactly where we stand.

Industry Update · April 2026

GLP-1s Reach Mass Adoption

1 in 8 Americans are now using GLP-1 therapies. Next-generation drugs like retatrutide are delivering nearly 30% weight loss, and emerging research is positioning them as early-stage longevity treatments, expanding the market well beyond weight loss.

For Castle Rock, this signals a critical opportunity: demand is outpacing provider capacity, and the market is shifting from transactional prescribing toward structured, long-term care protocols. That is precisely the model Castle Rock is built around.

"The market is no longer defined by access. It's defined by performance, outcomes, and long-term health impact."

Market Intelligence

Hormone Health Enters a New Growth Phase

The broader HRT market, spanning testosterone, metabolic care, and women's health, is projected to grow from $19B in 2026 to $33.7B by 2036. What was once a collection of separate treatment categories is now converging into a unified, multi-service healthcare ecosystem.

Younger men are entering TRT earlier for optimization rather than medical necessity. Women are demanding better hormonal solutions. Metabolic care is evolving into long-term lifestyle medicine. This convergence favors platforms over single-service providers.

Castle Rock's advantage: We are architected precisely for this moment.

Franchise Update

The Opportunity Ahead

Franchise Sidekick Launch

Expanding our proprietary platform to streamline operations, drive performance, and accelerate unit growth across every location.

Castle Rock University

Empowering providers and teams with best-in-class clinical education, systems, and leadership development.

Category Leadership

Setting the standard in compliance, clinical excellence, and patient outcomes across proactive hormone health.

Partner Momentum

Strengthening relationships with vendors, investors, and strategic partners aligned with our long-term vision.

Built with purpose. Scaling with excellence.